Possible step-up in prevalence for Escherichia coli ST131 from fecal to clinical isolates: inferred virulence potential comparative studies within phylogenetic group B2

Table 1 Prevalence of ST131 among Escherichia coli isolates in relation to source, ciprofloxacin phenotype, and phylogenetic group

Host group	Isolate subgroup	Prevalence of ST131, proportion (%)		P value^c
Host group	Isolate subgroup	Fecal^a	Clinical^b	P value^c
Children	Total population	14/508 (3)	32/395 (8)	0.02
	Ciprofloxacin-resistant	4/17 (24)	15/32 (47)	< 0.001
	Group B2	14/106 (13)	32/237 (14)	NS^d
Women	Total population	23/458 (5)	124/623 (20)	< 0.001
	Ciprofloxacin-resistant	7/30 (23)	65/83 (78)	< 0.001
	Group B2	23/78 (29)	124/398 (31)	NS
Men	Total population	8/401 (2)	49/389 (13)	< 0.001
	Ciprofloxacin-resistant	5/14 (35)	27/35 (77)	< 0.001
	Group B2	8/64 (13)	49/241 (20)	0.021

^aFecal isolates from healthy subjects, matched by age, time, and location to the clinical isolates
^bUrine isolates from patients with cystitis
^cP values (by Fisher’s exact test) are show where P < 0.05
NS^d: Not significant; P values > 0.05

ISSN: 1423-0127